vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Leonardo DRS, Inc. (DRS). Click either name above to swap in a different company.

Leonardo DRS, Inc. is the larger business by last-quarter revenue ($1.1B vs $749.2M, roughly 1.4× CLOVER HEALTH INVESTMENTS, CORP.). Leonardo DRS, Inc. runs the higher net margin — 9.6% vs 3.6%, a 6.0% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (62.0% vs 8.1%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (45.0% CAGR vs 24.1%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Leonardo DRS, Inc. is a United States–based defense contractor. Originally founded as DRS Technologies, Inc. and traded on the NYSE, it was acquired by Leonardo’s predecessor Finmeccanica in 2008. Leonardo DRS provides advanced defense technologies and systems primarily to the U.S. military.

CLOV vs DRS — Head-to-Head

Bigger by revenue
DRS
DRS
1.4× larger
DRS
$1.1B
$749.2M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+54.0% gap
CLOV
62.0%
8.1%
DRS
Higher net margin
DRS
DRS
6.0% more per $
DRS
9.6%
3.6%
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
45.0%
24.1%
DRS

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CLOV
CLOV
DRS
DRS
Revenue
$749.2M
$1.1B
Net Profit
$27.3M
$102.0M
Gross Margin
25.4%
Operating Margin
3.6%
11.9%
Net Margin
3.6%
9.6%
Revenue YoY
62.0%
8.1%
Net Profit YoY
14.6%
EPS (diluted)
$0.05
$0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
DRS
DRS
Q1 26
$749.2M
Q4 25
$487.7M
$1.1B
Q3 25
$496.6M
$960.0M
Q2 25
$477.6M
$829.0M
Q1 25
$462.3M
$799.0M
Q4 24
$337.0M
$981.0M
Q3 24
$331.0M
$812.0M
Q2 24
$356.3M
$753.0M
Net Profit
CLOV
CLOV
DRS
DRS
Q1 26
$27.3M
Q4 25
$-49.3M
$102.0M
Q3 25
$-24.4M
$72.0M
Q2 25
$-10.6M
$54.0M
Q1 25
$-1.3M
$50.0M
Q4 24
$-22.1M
$89.0M
Q3 24
$-9.2M
$57.0M
Q2 24
$7.4M
$38.0M
Gross Margin
CLOV
CLOV
DRS
DRS
Q1 26
Q4 25
25.4%
Q3 25
23.1%
Q2 25
23.8%
Q1 25
22.7%
Q4 24
24.0%
Q3 24
24.5%
22.0%
Q2 24
30.3%
22.4%
Operating Margin
CLOV
CLOV
DRS
DRS
Q1 26
3.6%
Q4 25
-10.1%
11.9%
Q3 25
-4.9%
9.7%
Q2 25
-2.2%
8.4%
Q1 25
-0.3%
7.4%
Q4 24
-6.4%
12.2%
Q3 24
-2.7%
9.2%
Q2 24
2.0%
7.3%
Net Margin
CLOV
CLOV
DRS
DRS
Q1 26
3.6%
Q4 25
-10.1%
9.6%
Q3 25
-4.9%
7.5%
Q2 25
-2.2%
6.5%
Q1 25
-0.3%
6.3%
Q4 24
-6.6%
9.1%
Q3 24
-2.8%
7.0%
Q2 24
2.1%
5.0%
EPS (diluted)
CLOV
CLOV
DRS
DRS
Q1 26
$0.05
Q4 25
$0.38
Q3 25
$0.26
Q2 25
$0.20
Q1 25
$0.19
Q4 24
$0.34
Q3 24
$0.21
Q2 24
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
DRS
DRS
Cash + ST InvestmentsLiquidity on hand
$177.6M
$647.0M
Total DebtLower is stronger
$321.0M
Stockholders' EquityBook value
$339.4M
$2.7B
Total Assets
$697.7M
$4.5B
Debt / EquityLower = less leverage
0.12×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
DRS
DRS
Q1 26
$177.6M
Q4 25
$78.3M
$647.0M
Q3 25
$309.0M
Q2 25
$278.0M
Q1 25
$380.0M
Q4 24
$194.5M
$598.0M
Q3 24
$288.0M
$198.0M
Q2 24
$254.8M
$149.0M
Total Debt
CLOV
CLOV
DRS
DRS
Q1 26
Q4 25
$321.0M
Q3 25
$326.0M
Q2 25
$331.0M
Q1 25
$335.0M
Q4 24
$340.0M
Q3 24
$345.0M
Q2 24
$351.0M
Stockholders' Equity
CLOV
CLOV
DRS
DRS
Q1 26
$339.4M
Q4 25
$308.7M
$2.7B
Q3 25
$340.9M
$2.6B
Q2 25
$344.2M
$2.6B
Q1 25
$336.1M
$2.6B
Q4 24
$341.1M
$2.6B
Q3 24
$342.2M
$2.5B
Q2 24
$324.9M
$2.4B
Total Assets
CLOV
CLOV
DRS
DRS
Q1 26
$697.7M
Q4 25
$541.0M
$4.5B
Q3 25
$559.7M
$4.2B
Q2 25
$575.0M
$4.1B
Q1 25
$583.7M
$4.1B
Q4 24
$580.7M
$4.2B
Q3 24
$653.0M
$3.9B
Q2 24
$674.2M
$3.8B
Debt / Equity
CLOV
CLOV
DRS
DRS
Q1 26
Q4 25
0.12×
Q3 25
0.12×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.14×
Q2 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
DRS
DRS
Operating Cash FlowLast quarter
$425.0M
Free Cash FlowOCF − Capex
$376.0M
FCF MarginFCF / Revenue
35.5%
Capex IntensityCapex / Revenue
4.6%
Cash ConversionOCF / Net Profit
4.17×
TTM Free Cash FlowTrailing 4 quarters
$227.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
DRS
DRS
Q1 26
Q4 25
$-66.9M
$425.0M
Q3 25
$12.1M
$107.0M
Q2 25
$5.4M
$-28.0M
Q1 25
$-16.3M
$-138.0M
Q4 24
$34.8M
$443.0M
Q3 24
$50.0M
$59.0M
Q2 24
$44.8M
$34.0M
Free Cash Flow
CLOV
CLOV
DRS
DRS
Q1 26
Q4 25
$-69.0M
$376.0M
Q3 25
$11.4M
$77.0M
Q2 25
$4.8M
$-56.0M
Q1 25
$-16.5M
$-170.0M
Q4 24
$33.3M
$414.0M
Q3 24
$49.6M
$47.0M
Q2 24
$44.4M
$0
FCF Margin
CLOV
CLOV
DRS
DRS
Q1 26
Q4 25
-14.1%
35.5%
Q3 25
2.3%
8.0%
Q2 25
1.0%
-6.8%
Q1 25
-3.6%
-21.3%
Q4 24
9.9%
42.2%
Q3 24
15.0%
5.8%
Q2 24
12.5%
0.0%
Capex Intensity
CLOV
CLOV
DRS
DRS
Q1 26
Q4 25
0.4%
4.6%
Q3 25
0.1%
3.1%
Q2 25
0.1%
3.4%
Q1 25
0.0%
4.0%
Q4 24
0.5%
3.0%
Q3 24
0.1%
1.5%
Q2 24
0.1%
4.5%
Cash Conversion
CLOV
CLOV
DRS
DRS
Q1 26
Q4 25
4.17×
Q3 25
1.49×
Q2 25
-0.52×
Q1 25
-2.76×
Q4 24
4.98×
Q3 24
1.04×
Q2 24
6.04×
0.89×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons